Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. BioNTech SE
  6. News
  7. Summary
    BNTX   US09075V1026

BIONTECH SE

(BNTX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

FDA May Soon Allow Mix-and-Match COVID-19 Booster Shots

10/19/2021 | 04:28am EST


© MT Newswires 2021
All news about BIONTECH SE
11:38aHardest hit German state Saxony to give COVID-19 shot to younger children early
RE
08:32aAfrica needs to make own vaccines but hurdles are high, experts say
RE
07:45aMarketScreener's World Press Review - December 7, 2021
07:16aEU agencies endorse mix-and-match of COVID-19 vaccines
RE
01:16aPfizer And BioNTech To Request Approval For Vaccine Use In 12-To-15-Year-Olds – M..
AQ
12/06AstraZeneca, Pfizer-BioNTech's COVID-19 Jabs Work Well With Moderna Shot, UK Study Says
MT
12/06Mixing Pfizer, AstraZ COVID-19 shots with Moderna gives better immune response -UK stud..
RE
12/06COVID-19 Reopening Plays Among Top Gainers While Vaccine Makers Tumble on Reports Omicr..
MT
12/06European ADRs Climb Higher in Monday Trading
MT
12/06BofA Securities Adjusts Price Target on BioNTech SE to $349 From $341, Maintains Neutra..
MT
More news
Analyst Recommendations on BIONTECH SE
More recommendations
Financials
Sales 2021 17 474 M 19 659 M 19 659 M
Net income 2021 9 220 M 10 372 M 10 372 M
Net cash 2021 9 793 M 11 018 M 11 018 M
P/E ratio 2021 6,76x
Yield 2021 -
Capitalization 59 905 M 67 585 M 67 393 M
EV / Sales 2021 2,87x
EV / Sales 2022 2,34x
Nbr of Employees 2 800
Free-Float 87,3%
Chart BIONTECH SE
Duration : Period :
BioNTech SE Technical Analysis Chart | BNTX | US09075V1026 | MarketScreener
Technical analysis trends BIONTECH SE
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 15
Last Close Price 248,03 €
Average target price 261,13 €
Spread / Average Target 5,28%
EPS Revisions
Managers and Directors
Ugur Sahin Chief Executive Officer
Jens Holstein Chief Financial Officer
Helmut Jeggle Chairman-Supervisory Board
Özlem Türeci Chief Medical Officer
Sierk Pötting Chief Operating Officer
Sector and Competitors
1st jan.Capi. (M$)
BIONTECH SE310.30%67 585
GILEAD SCIENCES, INC.19.29%87 180
REGENERON PHARMACEUTICALS29.37%65 347
WUXI APPTEC CO., LTD.21.75%63 017
VERTEX PHARMACEUTICALS-13.24%52 137
BEIGENE, LTD.21.58%30 750